1. Federal Jury Finds “Worst of Worst” Offender from Albuquerque Guilty ...
17 aug 2016 · ALBUQUERQUE – A federal jury sitting in Albuquerque, N.M., returned a verdict late yesterday afternoon finding Samuel Silva, 40, guilty on ...
ALBUQUERQUE – A federal jury sitting in Albuquerque, N.M., returned a verdict late yesterday afternoon finding Samuel Silva, 40, guilty on carjacking and firearms charges arising from a one-day crime spree in April 2014, following a two-day trial. Another federal jury previously convicted Silva on an armed career criminal charge in July 2016.
2. AZD1222/ChAdOx1 nCoV-19 vaccination induces a ...
AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus ...
Polyfunctional CD4+ and CD8+ T cell responses are elicited against the SARS-CoV-2 spike protein after two doses of the AZD1222 COVID-19 vaccine.
3. Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic ...
8 jun 2023 · Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol.
Data on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients with ARD using established diagnosis criteria. Retrospective evaluation of a prospective cohort of 108 ARD patients and 32 non-ARD controls, diagnosed with SARS-CoV-2 infection (RT-PCR/antigen test) after the third dose of the CoronaVac vaccine. Post-acute COVID-19 (≥ 4 weeks and > 12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria. ARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of ≥ 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p = 0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p = 0.5419). Regarding ≥ 4 weeks post-acute COVID-19, frequencies of ≥ 3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p = 0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p = 0.1322). Further analysis of the risk factors for ≥ 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p > 0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p > 0.05),...
4. Samuel Silva ("Caveira") | MMA Fighter Page - Tapology
Samuel "Caveira" Silva (12-4-1) is a Pro MMA Fighter out of Curitiba, Parana, Brazil and the #9th ranked Pro Mens Lightweight in Brazil.
Samuel "Caveira" Silva (12-4-1) is a Pro MMA Fighter out of Curitiba, Parana, Brazil and the #9th ranked Pro Mens Lightweight in Brazil. View complete Tapology profile, bio, rankings, photos, news and record.
5. SAMUEL SILVA | BITE
Bevat niet: vaccinated | Resultaten tonen met:vaccinated
Samuel Silva graduated in Biomedical Sciences at the University Institute of Health Sciences (IUCS, Gandra, Portugal) in 2017. In 2020 he completed an MSc in
6. Nome do vacinado - Prefeitura de Caririaçu
SAMUEL JONAS SILVA COSTA IDADE: 28, IDADE PESSOAS ... JANSSEN COVID-19 VACCINE (DOSE ÚNICA), 1 DOSE ... JANSSEN COVID-19 VACCINE (DOSE ÚNICA), 2 DOSES.
Pagina do vacinômetro
7. [PDF] PLGA-based particulate vaccine delivery systems for ...
Author: Monteiro Garrido Castro e Silva, Ana Luisa (Ana Luisa Silva) ... Fail better.” Samuel Beckett. Aos meus pais. Page 8 ... Synthetic long peptide-based ...
8. [PDF] Structural and procedural conditions in National Immunization Program ...
Samuel Barroso RodriguesI. ORCID: 0000-0002-9832 ... Silva BS, Souza KC, Souza RG, Rodrigues SB ... 73. 6. Community Preventive Services Task Force. Recommendation ...
9. Impact of vaccine platform and BCG vaccination on antibody responses ...
Paulo Victor Rocha da Silva, Débora dos Santos Silva, Patricia Vieira da Silva, Bruno Freitas da ... Samuel Stone, Dr Lorrie Symons,. Harry Tripp, Prof ...
See AlsoPathfinder 2E ForumsMultiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and C...
10. COVID-19 Heroes Archives - USC Today
Samuel Roberts' dad passed away just before COVID vaccines became widely available. Since then, the USC Price Master of Public Policy student has worked to ...
University of Southern California News
11. T cell and antibody responses induced by a single dose of ...
17 dec 2020 · ... vaccinated animals after viral challenge. ... Silva, Karen J. Ford, Emma Francis, Lara ... Samuel Provstgaard-Morys, Helen Ratcliffe ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses2 and might reduce the potential for disease enhancement3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. 5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18–55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8+...
12. Nome do vacinado - Prefeitura de Itaitinga
SAMUEL DA SILVA LIMA IDADE: 12, 12 A 17 ANOS 12 A ... JANSSEN COVID-19 VACCINE (DOSE ÚNICA), 1 DOSE ... JANSSEN COVID-19 VACCINE (DOSE ÚNICA), 1 DOSE.
Pagina do vacinômetro
13. MAPCOMS carries out awareness campaign for immunization against ...
Odete da Silva Viegas asked the community to cooperate with the health sector to obtain the vaccine, in order to avoid the contagion of the deadly virus, and to ...
The Ministry of Parliamentary Affairs and Social Communications, Francisco da Costa Pereira Jerónimo, encouraged the community of Manatuto to receive the vaccine, although health data shows that the number of vaccinations reached 44 percent of the population, or 46, 000 forty six thousand people already vaccinated.
14. Mucosal Vaccination with UV-Inactivated Chlamydia suis in ...
Sam Y. Omesi. Sam Y. Omesi. SciProfiles Scilit ... vaccination (10 days post challenge) in the TriAdj vaccinated pigs. ... Silva, D.; Hunt, T.; et al. Structural ...
Chlamydia trachomatis (Ct) infections are the most frequent bacterial sexually transmitted disease, and they can lead to ectopic pregnancy and infertility. Despite these detrimental long-term sequelae, a vaccine is not available. Success in preclinical animal studies is essential for vaccines to move to human clinical trials. Pigs are the natural host to Chlamydia suis (Cs)—a chlamydia species closely related to Ct, and are susceptible to Ct, making them a valuable animal model for Ct vaccine development. Before making it onto market, Ct vaccine candidates must show efficacy in a high-risk human population. The high prevalence of human Ct infection combined with the fact that natural infection does not result in sterilizing immunity, results in people at risk likely having been pre-exposed, and thus having some level of underlying non-protective immunity. Like human Ct, Cs is highly prevalent in outbred pigs. Therefore, the goal of this study was to model a trial in pre-exposed humans, and to determine the immunogenicity and efficacy of intranasal Cs vaccination in pre-exposed outbred pigs. The vaccine candidates consisted of UV-inactivated Cs particles in the presence or absence of an adjuvant (TriAdj). In this study, both groups of vaccinated pigs had a lower Cs burden compared to the non-vaccinated group; especially the TriAdj group induced the differentiation of CD4+ cells into tissue-trafficking CCR7- IFN-γ-producing effector memory T cells. These results indicate that C...
15. National Immunization Program Information System: implementation ...
21 apr 2020 · Pinheiro ALS, Andrade KTS, Silva DO, Zacharias FCM, Gomide MFS, Pinto IC. Health Management: the use of information systems and knowledge ...
The National Immunization Program Information System (SIPNI - Sistema de Informação do Programa Nacional de Imunização) in Brazil is a technological innovation management tool that enhances the performance of managers and health professionals in the evaluation and monitoring of immunization activities. In the country, the decentralization of the System is at an advanced stage, but it still faces challenges regarding its operation and use, impacting on its results. This study aims to evaluate the deployment of SIPNI in the state of Minas Gerais, in 2017. Cross-section study performed in Primary Healthcare vaccination rooms in 54 municipalities in the Brazilian state of Minas Gerais, in 2017. A multidimensional questionnaire was used with nursing professionals who work in vaccination rooms, containing questions about the structure (presence of an internet-connected computer, instruction manual, software version, IT professional for technical support, trained healthcare professional, use of communication channels to obtain system information) and the process (activities performed by the staff to operate the immunization information system) of their work. Those questions refer to the components of the information system: system management, immunized-patient records, and Movement of Immunobiological. Implementation Degree (ID) was defined by a score system with different weights for each criterion, according to the importance level observed in it, with a rating of: adequate, parti...
16. Leishmaniasis treatment, current therapy limitations and new ...
22 jun 2021 · Author Biographies ; Alexandre Silva Santiago, Universidade do Estado da Bahia ; Samuel Silva da Rocha Pita, Universidade Federal da Bahia.
As leishmanioses são um grupo de doenças negligenciadas causadas por protozoários intracelulares do gênero Leishmania. Suas principais formas clínicas são a tegumentar (LT) e a visceral (LV). Atualmente a terapêutica contra a leishmaniose baseia-se na utilização de cinco fármacos: os antimoniais pentavalentes, a anfotericina B e a sua formulação lipossômica, a miltefosina, a paromomicina e a pentamidina. Estes compostos apresentam limitações que dificultam a adesão do paciente ao tratamento como: a elevada toxicidade e a necessidade de administração prolongada por via parenteral, além da possível seleção de cepas resistentes. Assim, utilizando a revisão narrativa de literatura, buscou-se elucidar um panorama do tratamento atual da leishmaniose, seus mecanismos de ação elucidados, sua toxicidade atribuída, seus efeitos adversos e vias de administração. Para tanto, os dados mais atualizados disponíveis na literatura foram trazidos para facilitar o acesso às informações sobre as opções terapêuticas, além das novas alternativas terapêuticas e perspectivas de vacinas contra esta doença negligenciada.
